MARKET

EXEL

EXEL

Exelixis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

23.24
-0.48
-2.02%
Closed 17:54 09/24 EDT
OPEN
23.51
PREV CLOSE
23.72
HIGH
23.96
LOW
22.98
VOLUME
2.47M
TURNOVER
--
52 WEEK HIGH
27.80
52 WEEK LOW
13.67
MARKET CAP
7.18B
P/E (TTM)
26.08
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Exelixis Cabozantinib Data, And Other News: The Good, Bad And Ugly Of Biopharma
Exelixis reports data from COSMIC-021 trial of Cabozantinib.Agios reports final overall survival data for Tibsovo.Illumina boosts its oncology portfolio, announces to acquire GRAIL.
Seekingalpha · 4h ago
Mixed Data From ESMO Sets Up The Next Fight For Exelixis
The CheckMate-9ER of Cabometyx and Opdivo was successful, but not definitively superior to the established combo of Pfizer's Inlyta and Merck's Keytruda.The Cabo-Opdivo combo appeared to work better in sicker patients, and the better tolerability (notably lower discontinuations) could be another argument in its favor.I don't necessarily see Cabo-Opdivo becoming #1 in front-line RCC in the U.S., but I believe the combo can help drive U.S. RCC sales to $2.4 billion.Exelixis has some early-stage clinical assets, but the success of Cabo in RCC is the real key if the stock is to reach my $29 fair value estimate.
Seekingalpha · 17h ago
Morgan Stanley Maintains Equal-Weight on Exelixis, Raises Price Target to $29
Morgan Stanley maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and raises the price target from $23 to $29.
Benzinga · 2d ago
Exelixis reports early-stage study results from cabozantinib/atezolizumab combo in solid tumors
Exelixis ([[EXEL]] -3.8%) has announced interim analysis from ongoing Phase 1b (COSMIC-021) trial of Cabometyx (cabozantinib) in combination with Roche' Tecentriq (atezolizumab), for the treatment of locally advanced or metastatic solid tumors. Data
Seekingalpha · 3d ago
Exelixis Announces Results From Two Renal Cell Carcinoma Cohorts of the COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab
Exelixis, Inc. (NASDAQ: EXEL) today announced positive phase 1b clinical trial results for the combination of cabozantinib (CABOMETYX®) and atezolizumab (TECENTRIQ®) in patients with locally advanced or metastatic solid tumors. Data from two expansion cohorts of the COSMIC-021 trial was presented during
Business Wire · 3d ago
BMY/Exelixis Opdivo + Cabometyx shows survival benefits in late-stage kidney cancer study
Bristol Myers Squibb (BMY) and Exelixis (EXEL) announce results from the pivotal Phase 3 CheckMate -9ER trial evaluating patients with previously untreated advanced or metastatic renal cell carcinoma ((RCC)).A total of
Seekingalpha · 3d ago
Bristol Myers Squibb Exelixis Announced Saturday at ESMO 2020, Opdivo in Combination with CABOMETYX Demonstrates Significant Survival Benefits in Patients with Advanced Renal Cell Carcinoma in Pivotal Phase 3 CheckMate -9ER Trial
Bristol Myers Squibb (NYSE: BMY) and Exelixis, Inc.
Benzinga · 4d ago
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Significant Survival Benefits in Patients with Advanced Renal Cell Carcinoma in Pivotal Phase 3 CheckMate -9ER Trial
Opdivo in Combination with CABOMETYX Demonstrates Significant Survival Benefits in Patients with Advanced Renal Cell Carcinoma....
Business Wire · 5d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EXEL. Analyze the recent business situations of Exelixis through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EXEL stock price target is 31.46 with a high estimate of 40.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 522
Institutional Holdings: 267.65M
% Owned: 86.62%
Shares Outstanding: 309.00M
TypeInstitutionsShares
Increased
122
27.13M
New
120
-3.69M
Decreased
112
17.62M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.88%
Pharmaceuticals & Medical Research
-0.82%
Key Executives
Chairman/Co-Founder/Independent Director
Stelios Papadopoulos
Chief Executive Officer/President/Director
Michael Morrissey
Chief Financial Officer/Executive Vice President
Christopher Senner
Corporate Executive
Gisela Schwab
Executive Vice President/Chief Scientific Officer
Peter Lamb
Executive Vice President/General Counsel
Jeffrey Hessekiel
Executive Vice President
Patrick Haley
Independent Director
Charles Cohen
Independent Director
Carl Feldbaum
Independent Director
Maria Freire
Independent Director
Alan Garber
Independent Director
Vincent Marchesi
Independent Director
George Poste
Independent Director
Julie Smith
Independent Director
Lance Willsey
Independent Director
Jack Wyszomierski
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About EXEL
Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Exelixis, Inc. stock information, including NASDAQ:EXEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXEL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EXEL stock methods without spending real money on the virtual paper trading platform.